MS4A1 and myeloid sarcoma: Compared to untreated MS patients, alemtuzumab, dimethyl fumarate and fingolimod therapy decreased the absolute numbers of CD20+T cells whilst natalizumab increased these, suggesting that CD20+T cells enter the CNS via an α4-integrin-dependent manner [10].